Xolair Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Xolair Indications
Indications
Limitations of Use
Xolair Dosage and Administration
Adult
Children
Xolair Contraindications
Not Applicable
Xolair Boxed Warnings
Boxed Warning
Xolair Warnings/Precautions
Warnings/Precautions
Xolair Pharmacokinetics
Absorption
Following a single SC dose, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7–8 days.
Distribution
The apparent volume of distribution of omalizumab following SC administration was 78 ± 32 mL/kg.
Elimination
In CSU patients, at steady state, based on population pharmacokinetics, omalizumab serum elimination half-life averaged 24 days and apparent clearance averaged 240mL/day (corresponding to 3.0mL/kg/day for an 80kg patient).
Xolair Interactions
Interactions
Concomitant use of Xolair and allergen immunotherapy has not been evaluated.
Xolair Adverse Reactions
Adverse Reactions
Xolair Clinical Trials
Xolair Note
Notes
Xolair Patient Counseling
Cost Savings Program
The Xolair Co-Pay Program is available here.
Xolair Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Xolair Indications
Indications
Limitations of Use
Xolair Dosage and Administration
Adults and Children
Xolair Contraindications
Not Applicable
Xolair Boxed Warnings
Boxed Warning
Xolair Warnings/Precautions
Warnings/Precautions
Xolair Pharmacokinetics
Absorption
Following a single SC dose, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7–8 days.
Distribution
The apparent volume of distribution of omalizumab following SC administration was 78 ± 32 mL/kg.
Elimination
In asthma patients omalizumab serum elimination half-life averaged 26 days, with apparent clearance averaging 2.4 ± 1.1mL/kg/day. Doubling body weight approximately doubled apparent clearance.
Xolair Interactions
Interactions
Concomitant use of Xolair and allergen immunotherapy has not been evaluated.
Xolair Adverse Reactions
Adverse Reactions
Xolair Clinical Trials
Xolair Note
Notes
Xolair Patient Counseling
Cost Savings Program
The Xolair Co-Pay Program is available here.
Xolair Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Xolair Indications
Indications
Xolair Dosage and Administration
Adult
Children
Xolair Contraindications
Not Applicable
Xolair Boxed Warnings
Boxed Warning
Xolair Warnings/Precautions
Warnings/Precautions
Xolair Pharmacokinetics
Absorption
Following a single SC dose, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7–8 days.
Distribution
The apparent volume of distribution of omalizumab following SC administration was 78 ± 32 mL/kg.
Elimination
Clearance of omalizumab involved IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE.
Xolair Interactions
Interactions
Concomitant use of Xolair and allergen immunotherapy has not been evaluated.
Xolair Adverse Reactions
Adverse Reactions
Xolair Clinical Trials
Xolair Note
Notes
Xolair Patient Counseling
Cost Savings Program
The Xolair Co-Pay Program is available here.
Images
